Notably, many ongoing clinical trials are attempting to assess the application of TIGIT blockade or TIGIT blockade in combination with anti-PD-1/PD-L1, anti-CTLA-4 or anti-LAG-3 antibodies in the treatments for many cancers (53). Here, LAG3 is linked to cancer.